Blogs
Welcome to Unibest's Blogs section! Here, you will find valuable insights and in-depth reports covering various topics related to drugs and diseases. Our blogs aim to provide an enhanced understanding of the clinical significance and breakthroughs your clients can make. Stay updated with the latest trends, technological advancements, and industry analyses as we dive deep into the world of pharmaceuticals, giving you the knowledge and resources you need to stay ahead of the competition.

Selpercatinib

These are related to the Selpercatinib news, in which you can learn about the updated information in Selpercatinib, to help you better understand and expand Selpercatinib market. Because the market for Selpercatinib is evolving and changing, so we recommend that you collect our website, and we will show you the latest news on a regular basis.
  • Drug Patent & Exclusivity Expiration Report - Week of May 05 2025

    Drug Patent & Exclusivity Expiration Report - Week of May 05 2025

    2025-05-05

    This week, there are 9 drugs in the patent and exclusivity list. They are: - PFIZER INC's VIZIMPRO, containing active ingredient DACOMITINIB - SUMITOMO PHARMA AMERICA INC's APTIOM, containing active ingredient ESLICARBAZEPINE ACETATE - ASTRAZENECA LP's SYMBICORT, containing active ingredient BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE - NEURELIS INC's VALTOCO, containing active ingredient DIAZEPAM - NOVARTIS PHARMACEUTICAL CORP's TABRECTA, containing active ingredient CAPMATINIB HYDROCHLORIDE - ELI LILLY AND CO's RETEVMO, containing active ingredient SELPERCATINIB - BRISTOL MYERS SQUIBB CO's SPRYCEL, containing active ingredient DASATINIB - ASTRAZENECA PHARMACEUTICALS LP's BRILINTA, containing active ingredient TICAGRELOR - ELI LILLY AND CO's OLUMIANT, containing active ingredient BARICITINIB Read More